Stocktoria
enGene Therapeutics Inc. ENGN
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-12-10
enGene Therapeutics Inc. (ENGN) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
1/9
Piotroski F — financial health
-0.92
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Market cap$116M
Return on equity-69.9%
How it ranks in Manufacturing · percentile among 1906 companies
Piotroski Fstronger than 1%
Return on equitystronger than 24%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.765 |
| Retained earnings / assets | -1.68 |
| EBIT / assets | -0.556 |
| Equity / liabilities | 3.12 |
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | 1/9 | -0.92 | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
FAQ
Is ENGN financially healthy?
enGene Therapeutics Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ENGN pay a dividend?
No, enGene Therapeutics Inc. does not currently pay a dividend.
How profitable is ENGN?
In FY2025, enGene Therapeutics Inc. had a return on equity of -69.9%.
Source: SEC EDGAR filings · CIK 0001980845 · US · as of 2025-10-31. facts plus Stocktoria's own computed scores — not investment advice.